FDA approves Roche genetic test as an alternative to pap smear for cervical cancer screening
WASHINGTON - Federal health regulators have cleared a genetic test from Roche as the first U.S.-approved alternative to the pap smear, the decades-old mainstay of cervical cancer screening.
The Food and Drug Administration approved Roche's cobas HPV test to detect the human papillomavirus, or HPV, in women 25 and older. HPV causes nearly all cases of cervical cancer. Such DNA-based tests have been used for several years to confirm results from the pap tests. But Thursday's decision means Roche can now market the test as a stand-alone option for cervical cancer screening, without the pap test.
The decision comes despite pushback from a number of women's health groups, who warned regulators that approving the DNA test as an alternative to pap testing could lead to confusion, higher costs and overtreatment.
Read more Business News
- One injured in plane crashVernon / N. Okanagan - 11:40 am
- Parachutist hits houseVernon / N. Okanagan
- Boonstock liquor decision finalPenticton / S. Okanagan
- Sun shining on Copper SkyReal Estate - 11:38 am
|QHR Technologies Inc||1.19||+0.04|
|Anavex Life Sciences||0.26||-0.005|
|Copper Mountain Mining||2.89||-0.08|
|Sunrise Resources Ltd||0.025||+0.005|
|Mission Ready Services||0.17||-0.02|
Photo: Thinkstock.comWays to reduce your Debt:Make a budget and get budget counselingA basic first step for debt reduction is to prepare a budget and plan your spending. Once you have a budget, you mu...
The Big Picture Geopolitical tensions rattle markets The spectre of rising geopolitical tensions in Ukraine and Gaza cast a shadow over an otherwise positive week in the markets. News that a passenger...
Photo: ContributedI have the pleasure of witnessing people delegate tasks quite often. Sometimes with tremendous success and sometimes with disastrous consequences. I have chaired a lot of committees...